News coverage about NxStage Medical (NASDAQ:NXTM) has trended somewhat negative on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NxStage Medical earned a news impact score of -1.50 on their scale. InfoTrie also gave news articles about the medical device company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock’s share price in the immediate future.
Several equities research analysts recently issued reports on NXTM shares. BidaskClub upgraded NxStage Medical from a “sell” rating to a “hold” rating in a report on Friday, October 12th. Zacks Investment Research downgraded NxStage Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 11th. Finally, ValuEngine upgraded NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, October 12th.
Shares of NXTM stock traded up $0.43 on Friday, hitting $28.86. The stock had a trading volume of 458,771 shares, compared to its average volume of 577,105. The company has a market capitalization of $1.90 billion, a PE ratio of -131.18 and a beta of 0.05. NxStage Medical has a 1 year low of $22.70 and a 1 year high of $29.26.
NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Wednesday, November 7th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.03. The firm had revenue of $108.12 million for the quarter, compared to the consensus estimate of $108.07 million. NxStage Medical had a negative return on equity of 2.50% and a negative net margin of 1.29%. Sell-side analysts expect that NxStage Medical will post -0.02 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “NxStage Medical (NXTM) Earning Somewhat Negative Press Coverage, Report Shows” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/12/08/nxstage-medical-nxtm-earning-somewhat-negative-press-coverage-report-shows.html.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.